Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 13, 1997, Pages 2772-2780

  Weinreb, Robert N ^a   Kashiwagi, Kenji ^a   Kashiwagi, Fumiko ^a   Tsukahara, Shigeo ^b   Lindsey, James D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Glaucoma; Human ciliary muscle; Matrix metalloproteinases; Prostaglandins; Uveoscleral outflow

Indexed keywords

11 DEOXYPROSTAGLANDIN E1; CALCIUM; CASEIN; EDETIC ACID; GELATIN; MATRIX METALLOPROTEINASE; PROSTAGLANDIN F2 ALPHA; UNCLASSIFIED DRUG; ZINC;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CILIARY BODY EPITHELIUM; CONTROLLED STUDY; DENSITOMETRY; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; SCORING SYSTEM;

ADULT; AGED; ALPROSTADIL; BLOTTING, WESTERN; CELLS, CULTURED; CILIARY BODY; DINOPROST; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; METALLOENDOPEPTIDASES; MIDDLE AGED; MOLECULAR WEIGHT; MUSCLE, SMOOTH; PROSTAGLANDINS E, SYNTHETIC;

EID: 0031441685     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Camras C, Alm A, Watson P, Stjernschantz J, and the Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficiency and safety after 1 year treatment in 198 patients. Ophthalmology. 1996;103:1916-1924.
2. 2α analog, PhXA41 (latanoprost), for glaucoma management. J Lipid Mediat. 1993;6:535-543.
3. 2α increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989;49:389-402.
4. 2α. Arch Ophthalmol. 1987;105:1112-1116.
5. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707-716.
6. 2α analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297-1304.
7. 2α analog. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:513-518.
8. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993;4:197-250.
9. Woessner J Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 1991;5:2145-2154.
10. Lindsey JD, Kashiwagi K, Boyle D, et al. Prostaglandins increase pro-MMP-1 and pro-MMP-3 secretion by human ciliary smooth muscle cells. Curr Eye Res. 1996; 15:869-875.
11. Bill A. Uveoscleral drainage of aqueous humor: Physiology and pharmacology. Prog Clin Biol Res. 1989; 312:417-427.
12. Wood RL, Koseki T, Kelly DE. Uveoscleral permeability to intracamerally infused ferritin in eyes of rabbits and monkeys. Cell Tissue Res. 1992;270:559-567.
13. Weinreb RN, LindseyJ, Luo XX, WangT-H. Extracellular matrix of the human ciliary muscle. J Glaucoma. 1994;3:70-78.
14. 2α on calcium efflux. Invest Ophthalmol Vis Sci. 1992;33:2679-2686.
15. 2α. An ultrastructural study in rhesus and cynomolgus monkeys. Mech Ageing Dev. 1990;51:101-120.
16. Marshall GE, Konstas AG, Abraham S, Lee WR. Extracellular matrix in aged human ciliary body: An immunoelectron microscope study. Invest Ophthalmol Vis Sci. 1992;33:2546-2560.
17. Lindsey J, Kashiwagi K, Kashiwagi F, Weinreb R. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: Implications for uveoscleral outflow. Surv Ophthalmol. 1997;42(Suppl):S53-S59.
18. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
19. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci. 1995;748:501-507.
20. Fields G, Van Wart H, Birkedal-Hansen H. Sequence specificity of human skin fibroblast collagenase. Evidence for the role of collagen structure in determining the collagenase cleavage site. J Biol Chem. 1987;262:6221-6226.
21. Fields G. A model for interstitial collagen catabolism by mammalian collagenases. J Theor Biol. 1991; 153:585-602.
22. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays. 1992;14:455-463.
23. Kashiwagi K, Lindsey JD, Kashiwagi F, Tsukahara S, Weinreb RN. Calponin distribution in human ciliary muscle and other anterior segment tissues. Invest Ophthalmol Vis Sci. 1997;38:349-356.
24. Tamm E, Baur A, Lutjen-Drecoll E. Synthesis of extracellular matrix components by human ciliary muscle cells in culture. Curr Eye Res. 1992;11:333-341.
25. Basu S, Sjoquist B, Stjernschantz J, Resul B. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids. 1994;50:161-168.
26. 2α or epinephrine on cynomolgus monkey eyes. II Slit lamp biomicroscopy, aqueous humor analysis, and fluorescein angiography. Invest Ophthalmol Vis Sci. 1987; 28:921-926.
27. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol. 1989;109:877-889.
28. 2α in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci. 1994;35:242-250.
29. Kleiner D, Stetler-Stevenson W. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem. 1994;218:325-329.
30. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
31. Alexander JP, Bradley JM, Gabourel JD, Acott TS. Expression of matrix metalloproteinases and inhibitor by human retinal pigment epithelium. Invest Ophthalmol Vis Sci. 1990;31:2520-2528.
32. Frid MG, Shekhonin BV, Koteliansky VE, Glukhova MA. Phenotypic changes of human smooth muscle cells during development: Late expression of heavy caldesmon and calponin. Dev Biol. 1992;153:185-193.
33. Skalli O, Ropraz P, Trzeciak A, et al. A monoclonal antibody against alpha-smooth muscle actin: A new probe for smooth muscle differentiation. J Cell Biol. 1986;103:2787-2796.
34. Tamm E, Flugel C, Baur A, Lutjen-Drecoll E. Cell cultures of human ciliary muscle: Growth, ultrastructural and immunocytochemical characteristics. Exp Eye Res. 1991;53:375-387.
35. Jiang W, Bond JS. Families of metalloendopeptidases and their relationships. FEBS Lett. 1992;312:110-114.
36. Karin M, Yang-Yen HF, Chambard JC, Deng T, Saatcioglu F. Various modes of gene regulation by nuclear receptors for steroid and thyroid hormones. Eur J Clin Pharmacol. 1993;45:S9-S15.
37. Curran T, Franza B Jr. Fos and jun: the AP-1 connection. Cell. 1988;55:395-397.
38. Woodward DF, Lawrence RA, Fairbairn CE, Shan T, Williams LS. Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J Lipid Mediat. 1993;6:545-553.
39. Woodward D, Fairbairn C, Krauss H-P, Lawrence R, Protzman C. Radioligand binding analysis of receptor subtypes in two FP receptor preparations that exhibit different functional rank orders of potency in response to prostaglandins. J Pharmacol Exp Ther. 1995;273:285-291.
40. 2 subtype. Mol Pharmacol. 1994;46:213-220.
41. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta. 1995;1259:109-119.
42. Nagase H, Suzuki K, Morodomi T, EnghildJJ, Salvesen G. Activation mechanisms of the precursors of matrix metalloproteinases 1, 2, and 3. Matrix Suppl. 1992; 1:237-244.
43. Goldberg GI, Marmer BL, Grant GA, et al. Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci U S A. 1989;86:8207-8211.
44. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol. 1996;107:743-748.
45. Lindsey J, Kashiwagi K, Kashiwagi F, Weinreb R. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest Ophthalmol Vis Sci. 1997;38:2214-2223.
46. Woessner J Jr. Literature on vertebrate matrix metalloproteinases and their tissue inhibitors. Matrix Suppl. 1992;1:425-501.
47. Wilhelm SM, Collier IE, Kronberger A, et al. Human skin fibroblast stromelysin: Structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells. Proc Natl Acad Sci U S A. 1987;84:6725-6729.
48. Nagase H, Suzuki K, Enghild JJ, Salvesen G. Stepwise activation mechanisms of the precursors of matrix metalloproteinases 1 (tissue collagenase) and 3 (stromelysin). Biomed Biochim Acta. 1991;50:749-754.
49. Shapiro SD, Fliszar CJ, Broekelmann TJ, et al. Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem. 1995;270:6351-6356.
50. Nagase H, Fields GB. Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides. Biopolymers. 1996;40:399-416.
51. Bernatchez SF, Tabatabay C, Belin D. Urokinase-type plasminogen activator in human aqueous humor. Invest Ophthalmol Vis Sci. 1992;33:2687-2692.
52. Ando H, Twining SS, Yue BY, et al. MMPs and proteinase inhibitors in the human aqueous humor. Invest Ophthalmol Vis Sci. 1993;34:3541-3548.
53. Smalley DM, Fitzgerald JE, Taylor DM, Cone RE, O'Rourke J Tissue plasminogen activator activity in human aqueous humor. Invest Ophthalmol Vis Sci. 1994;35:48-53.
54. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther. 1993;59:329-341.
55. Barsotti M, Bartels S, Freddo T, Kamm R. The source of protein in the aqueous humor of the normal monkey eye. Invest Ophthalmol Vis Sci. 1992;33:581-595.
56. Weinreb RN, PolanskyJR, Alvarado JA, Mitchell MD. Arachidonic acid metabolism in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1988;29:1708-1712.
57. Weinreb RN, Mitchell MD. Prostaglandin production by cultured cynomolgus monkey trabecular meshwork cells. Prostaglandins Leukot Essent Fatty Acids. 1989; 36:97-100.
58. Polansky JR, Weinreb RN. Anterior segment inflammation and trabecular meshwork cell response. New Trends Lipid Mediators Res. 1990;5:56-64.
59. Shaw BR, Lindsey JD, Weinreb RN. Prostaglandin release in a perfused human anterior segment model. J Glaucoma. 1993;2:39-43.